A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV). The Study is Also Known as Aliskiren Trial of Minimizing OutcomeS in Patients With HEart Failure (ATMOSPHERE).

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV). The Study is Also Known as Aliskiren Trial of Minimizing OutcomeS in Patients With HEart Failure (ATMOSPHERE).

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs Aliskiren (Primary) ; Enalapril
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms ASPIRE-HIGHER; ATMOSPHERE
  • Sponsors Novartis
  • Most Recent Events

    • 25 Sep 2017 Results of subgroup analysis published in the European Journal of Heart Failure
    • 16 Nov 2016 Results (n=14,932) of PARADIGM-HF and ATMOSPHERE trials presented at the 89th Annual Scientific Sessions of the American Heart Association (2016).
    • 04 Apr 2016 Results published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top